Title: Determination of enantiomeric impurity in besifloxacin hydrochloride by chiral high-performance liquid chromatography with precolumn derivatization.
Journal: Chirality20120701
Title: Besifloxacin ophthalmic suspension, 0.6%: a novel topical fluoroquinolone for bacterial conjunctivitis.
Journal: Advances in therapy20120601
Title: Besifloxacin ophthalmic suspension 0.6% administered twice daily for 3 days in the treatment of bacterial conjunctivitis in adults and children.
Journal: Clinical drug investigation20120501
Title: Microbiological etiology and susceptibility of bacterial conjunctivitis isolates from clinical trials with ophthalmic, twice-daily besifloxacin.
Journal: Advances in therapy20120501
Title: Challenges in assessing microbial susceptibility and predicting clinical response to newer-generation fluoroquinolones.
Journal: Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics20120201
Title: Acute and twenty-eight days repeated oral dose toxicity study of besifloxacin in Wistar albino rats.
Journal: Environmental toxicology and pharmacology20110701
Title: Human aqueous humor concentrations of besifloxacin, moxifloxacin, and gatifloxacin after topical ocular application.
Journal: Journal of cataract and refractive surgery20110601
Title: In vitro time-kill experiments with besifloxacin, moxifloxacin and gatifloxacin in the absence and presence of benzalkonium chloride.
Journal: The Journal of antimicrobial chemotherapy20110401
Title: Evaluation of the effect of bacterial efflux pumps on the antibacterial activity of the novel fluoroquinolone besifloxacin.
Journal: Journal of chemotherapy (Florence, Italy)20110401
Title: Comparison of besifloxacin, gatifloxacin, and moxifloxacin against strains of pseudomonas aeruginosa with different quinolone susceptibility patterns in a rabbit model of keratitis.
Journal: Cornea20110101
Title: Relevance of aqueous humor concentrations of fluoroquinolones.
Journal: Journal of cataract and refractive surgery20110101
Title: Efficacy and tolerability of besifloxacin ophthalmic suspension 0.6% administered twice daily for 3 days in the treatment of bacterial conjunctivitis: a multicenter, randomized, double-masked, vehicle-controlled, parallel-group study in adults and children.
Journal: Clinical therapeutics20110101
Title: Topoisomerase mutations that are associated with high-level resistance to earlier fluoroquinolones in Staphylococcus aureus have less effect on the antibacterial activity of besifloxacin.
Journal: Chemotherapy20110101
Title: Penetration and effectiveness of prophylactic fluoroquinolones in experimental methicillin-sensitive or methicillin-resistant Staphylococcus aureus anterior chamber infections.
Journal: Journal of cataract and refractive surgery20101201
Title: An anterior chamber toxicity study evaluating Besivance, AzaSite, and Ciprofloxacin.
Journal: American journal of ophthalmology20101001
Title: Ocular pharmacokinetics/pharmacodynamics of besifloxacin, moxifloxacin, and gatifloxacin following topical administration to pigmented rabbits.
Journal: Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics20101001
Title: Aqueous penetration of moxifloxacin 0.5% ophthalmic solution and besifloxacin 0.6% ophthalmic suspension in cataract surgery patients.
Journal: Journal of cataract and refractive surgery20100901
Title: Bactericidal activity of besifloxacin against staphylococci, Streptococcus pneumoniae and Haemophilus influenzae.
Journal: The Journal of antimicrobial chemotherapy20100701
Title: Comparative effects of besifloxacin and other fluoroquinolones on corneal reepithelialization in the rabbit.
Journal: Journal of cataract and refractive surgery20100601
Title: Comparative efficacy of besifloxacin and other fluoroquinolones in a prophylaxis model of penicillin-resistant Streptococcus pneumoniae rabbit endophthalmitis.
Journal: Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics20100601
Title: Efficacy and safety of besifloxacin ophthalmic suspension 0.6% in children and adolescents with bacterial conjunctivitis: a post hoc, subgroup analysis of three randomized, double-masked, parallel-group, multicenter clinical trials.
Journal: Paediatric drugs20100401
Title: Efficacy of besifloxacin in an early treatment model of methicillin-resistant Staphylococcus aureus keratitis.
Journal: Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics20100401
Title: Besifloxacin: a topical fluoroquinolone for the treatment of bacterial conjunctivitis.
Journal: Clinical therapeutics20100301
Title: New Drugs2010, PART 1.
Journal: Nursing20100201
Title: Besifloxacin ophthalmic suspension 0.6%.
Journal: Drugs20100101
Title: Safety and tolerability of besifloxacin ophthalmic suspension 0.6% in the treatment of bacterial conjunctivitis: data from six clinical and phase I safety studies.
Journal: Clinical drug investigation20100101
Title: Efficacy of besifloxacin in a rabbit model of methicillin-resistant Staphylococcus aureus keratitis.
Journal: Cornea20091001
Title: Besifloxacin, a new ophthalmic fluoroquinolone for the treatment of bacterial conjunctivitis.
Journal: Expert opinion on pharmacotherapy20091001
Title: Efficacy and safety of besifloxacin ophthalmic suspension 0.6% compared with moxifloxacin ophthalmic solution 0.5% for treating bacterial conjunctivitis.
Journal: Ophthalmology20090901
Title: Ocular pharmacokinetics of besifloxacin following topical administration to rabbits, monkeys, and humans.
Journal: Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics20090801
Title: Besifloxacin ophthalmic suspension for bacterial conjunctivitis.
Journal: Drugs of today (Barcelona, Spain : 1998)20090801
Title: Phase III efficacy and safety study of besifloxacin ophthalmic suspension 0.6% in the treatment of bacterial conjunctivitis.
Journal: Current medical research and opinion20090501
Title: Target specificity of the new fluoroquinolone besifloxacin in Streptococcus pneumoniae, Staphylococcus aureus and Escherichia coli.
Journal: The Journal of antimicrobial chemotherapy20090301
Title: Besifloxacin ophthalmic suspension 0.6% in patients with bacterial conjunctivitis: A multicenter, prospective, randomized, double-masked, vehicle-controlled, 5-day efficacy and safety study.
Journal: Clinical therapeutics20090301
Title: New drugs: golimumab, besifloxacin hydrochloride, and artemether/lumefantrine.
Journal: Journal of the American Pharmacists Association : JAPhA20090101
Title: Anti-inflammatory effects of besifloxacin, a novel fluoroquinolone, in primary human corneal epithelial cells.
Journal: Current eye research20081101
Title: Quantitative determination of besifloxacin, a novel fluoroquinolone antimicrobial agent, in human tears by liquid chromatography-tandem mass spectrometry.
Journal: Journal of chromatography. B, Analytical technologies in the biomedical and life sciences20080501
Title: Besifloxacin, a novel fluoroquinolone antimicrobial agent, exhibits potent inhibition of pro-inflammatory cytokines in human THP-1 monocytes.
Journal: The Journal of antimicrobial chemotherapy20080101
Title: Nonclinical pharmacodynamics, pharmacokinetics, and safety of BOL-303224-A, a novel fluoroquinolone antimicrobial agent for topical ophthalmic use.
Journal: Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics20070601
Title: Wang Z, Wang S, Zhu F, Chen Z, Yu L, Zeng S.Determination of enantiomeric impurity in besifloxacin hydrochloride by chiral high-performance liquid chromatography with precolumn derivatization.Chirality. 2012 Jul;24(7):526-31. doi: 10.1002/chir.22042.
Title: Hussar DA.New drugs: golimumab, besifloxacin hydrochloride, and artemether/lumefantrine.J Am Pharm Assoc (2003). 2009 Jul-Aug;49(4):570-4.
Title: Nafziger AN, Bertino JS Jr.Besifloxacin ophthalmic suspension for bacterial conjunctivitis.Drugs Today (Barc). 2009 Aug;45(8):577-88.
Title: Proksch JW, Ward KW.Ocular pharmacokinetics/pharmacodynamics of besifloxacin, moxifloxacin, and gatifloxacin following topical administration to pigmented rabbits.J Ocul Pharmacol Ther. 2010 Oct;26(5):449-58.
Title: Comstock TL, Paterno MR, Usner DW, Pichichero ME.Efficacy and safety of besifloxacin ophthalmic suspension 0.6% in children and adolescents with bacterial conjunctivitis: a post hoc, subgroup analysis of three randomized, double-masked, parallel-group, multicenter clinical trials.Paediatr Drugs. 2010 Apr 1;12(2):105-12. doi: 10.2165/11534380-000000000-00000.
